Want to see GB:BVXP full AI Analyst Report?
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,300.00 p - 2,800.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£80.99M
Enterprise Value95.58 p
Total Cash (Recent Filing)£5.30M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)10.9
Beta0.62
Next Earnings
Oct 26, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend Yield9.68%
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.94
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Royalty-backed Recurring RevenueBioventix's core model earns royalties and reagent sales from diagnostic assays with long lifecycles. Once an antibody is adopted into a commercial test, royalties create annuity-like revenue tied to test volumes, providing durable, predictable cash streams and high customer switching costs.
High Profitability And MarginsThe company sustains exceptionally high gross and net margins, reflecting pricing power from proprietary high-affinity antibodies and low variable costs. Margin durability supports strong free cash flow, resilience to moderate revenue volatility, and high returns on invested capital over time.
Conservative Balance Sheet And Cash ConversionZero debt plus very strong cash conversion (free cash flow tracking net income) gives financial flexibility to fund dividends, R&D or buffer cyclical dips. A conservative capital structure lowers refinancing risk and preserves optionality during extended industry cycles.
Bears Say
Recent Revenue & Cashflow SlowdownReported declines in 2025 revenue and free cash flow interrupt prior growth trends and reduce the compounding base for royalties. If prolonged, slower end-market test volumes would materially weaken recurring income and limit the firm's ability to grow dividends or reinvest at prior rates.
Small Scale And Concentration RiskA tiny organizational footprint implies limited operational scale and reliance on a small number of large IVD partners and products. Customer/concentration risk and limited internal capacity for simultaneous development projects increase vulnerability if a major customer shifts suppliers or key assays decline.
Exposure To Market Headwinds And Asset DriftManagement flagged 2025 revenue/profit decline and external pressure (notably China), indicating structural demand risks in key markets. Coupled with noted drift down in equity/assets, this reduces the balance sheet buffer and heightens the risk that external market weakness erodes future royalty streams.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 2800.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £80.99M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 26, 2026 which is in 97 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.513 p by 0.171 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 70 p which represents an annual dividend yield of 9.68%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 0.66.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.513 p. Following the earnings report the stock price went up 6.909%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth £9.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
9.68%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―